ATC Group: J06BD07 Casirivimab and imdevimab

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of J06BD07 in the ATC hierarchy

Level Code Title
1 J Antiinfectives for systemic use
2 J06 Immune sera and immunoglobulins
3 J06B Immunoglobulins
4 J06BD Antiviral monoclonal antibodies
5 J06BD07

Active ingredients in J06BD07

Active Ingredient Description
Casirivimab and imdevimab

Casirivimab (IgG1Îș) and imdevimab (IgG1λ) are two recombinant human monoclonal antibodies which are unmodified in the Fc regions. Casirivimab and imdevimab bind to non-overlapping epitopes of the spike protein receptor binding domain (RBD) of SARS-CoV-2. This prevents RBD binding to the human ACE2 receptor, so preventing virus entry into cells.

Related product monographs

Title Information Source Document Type  
RONAPREVE Solution for injection/infusion Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC

Medicines in this ATC group

Austria (AT)

Croatia (HR)

Estonia (EE)

France (FR)

Ireland (IE)

Italy (IT)

Japan (JP)

Lithuania (LT)

New Zealand (NZ)

Poland (PL)

Romania (RO)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.